BioCrowd highlights the Unified Funding Strategy that keeps peer review at its center.

In microgravity, biology does things it can't do on Earth — purer protein crystals, novel formulations, and disease models that accelerate drug discovery. The science is extraordinary. The capital to commercialize it barely exists. That's the pattern across medical research: breakthroughs stall in the gap between grants and institutional funding — the "Valley of Death." That's not a science problem. It's a capital and infrastructure problem. BioCrowd is the capital and commercialization layer for translational research, from academic labs to the frontier of space biopharma. We turn research progress into milestone-driven, investable assets — accelerating IP innovation and making it easier to distribute life-changing ownership and royalties across the life of the IP. How it works: → Capital deployed directly into lab-level research → Milestone-based funding aligned with FDA pathways → A marketplace to invest in IP rights and future cash flows, using SEC-compliant private securities → Transparent reporting for donors and institutions We're building a decentralized open-science (DeSci) accelerator on an equity- and royalty-tokenized blockchain platform — connecting early-stage companies and researchers with investors, patients, and community. Projects can raise capital, secure non-dilutive funding, and reward early collaborators and patient groups with equity or revenue-share royalties. For investors: the NASDAQ of FDA milestones. For institutions: a new capital stack alongside NIH and grants. For scientists and patients: a faster path to fund — and share in — the next cure. ▶ Watch our intro: https://youtu.be/-OiK9MOVxLs We're accepting projects for funding now — and welcoming experts and contributors to join. If the next breakthrough is limited not by science, but by capital — let's talk.